Mature T-cell leukemias/lymphomas (MaTCL) are rare blood cancers for which there are not many effective treatments available. Recent research by our consortium members and others have revealed new information on the genetics of these diseases. Particularly, mutations in genes from an important cell growth and survival pathway, called JAK/STAT, are found to be very common in these types of blood cancers. In the JAKSTAT-TARGET project our aim is to investigate the causes and consequences of JAK/STAT mutations, and understand how different mutations in individual patients may impact their treatment. We also aim to test new treatment options and drug combinations in relevant in vivo models and patient samples. Finally, we will combine all of our research data and translate it to personalized treatment options for patients. Our consortium consists of international experts in various fields such as in hematology (blood diseases), immunology, clinical medicine, computational science and chemistry. Together with our unique resources, our project will create individualized therapy options and strategies to predict treatment response for MaTCL patients.
